Skip to main content

Table 1 The inhibitory effect of NTZ and tizoxanide (TIZ) as broad spectrum antivirals

From: Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Virus Dose Compound Ref
Canine coronavirus S-378 IC50, 1 μg/ml TIZ [9]
Bovine coronavirus (L9) IC50, 0.3 μg/ml NTZ [12]
Murine coronavirus IC50, 0.3 μg/ml NTZ [12]
Mouse hepatitis virus (A59) IC50, 0.3 μg/ml NTZ [12]
Human enteric coronavirus (4408) IC50, 0.3 μg/ml NTZ [12]
MERS-CoV IC50, 0.92 μg/ml NTZ [12]
MERS-CoV IC50, 0.83 μg/ml TIZ [12]
SARS-CoV-2 IC50, 2.12 μM NTZ [1]
Influenza A strains IC50, 0.2–1.5 μg/ml TIZ [9]
Influenza B/Parma/3/04 IC50, 0.2–1.5 μg/ml TIZ [9]
Rotavirus: the human Wa-G1P (8) IC50, 1 μg/ml TIZ [9]
Rotavirus: simian SA11-G3P (2) IC50, 0.5 μg/ml TIZ [9]
Norovirus G1 replicon assay system IC50, 0.5 μg/ml TIZ [13]
Human astrovirus IC50, 1.47 μM NTZ [14]
Adenovirus enteritis 500 mg twice daily NTZ [15]
Paramyxovirus IC50, 10 μg/ml NTZ [16]
Ebola virus IC100, 20–40 μM NTZ [17]
HCV genotype 1a IC50, 0.09 μg/ml TIZ [18]
HCV genotype 1b IC50, 0.06 μg/ml TIZ [18]
HBV in clinical trials 500 mg daily NTZ [11]
Chikungunya virus IC50, 2.96 μM NTZ [19]
Rubella virus IC50, 0.35 μg/ml NTZ [20]
Vaccinia virus IC50, 2 μM NTZ [21]
HIV IC50, 0.5 μg/ml NTZ [22]
HIV IC50, 0.5 μg/ml TIZ [22]
Human cytomegalovirus IC50, 3.2 μM NTZ [23]
Dengue-2 virus IC50, 0.1 μg/ml TIZ [24]
Yellow fever virus IC50, 0.06 μg/ml TIZ [24]
Japanese encephalitis IC50, 0.12 μg/ml NTZ [25]
\